Keywords: Psychiatric Disorders, Psychiatric Disorders, MRS, MDD, Neurotransmitters, UHF
Motivation: This research addresses a critical gap by investigating the impact of depression treatment on neurometabolites in the PCC.
Goal(s): This exploratory study aims to investigate the relationship between neurometabolite levels in the PCC and assess its impact on treatment.
Approach: Structural MRI and MRS data were acquired from 16 MDD patients and 16 healthy controls. The concentration of neurometabolites was quantified. ANOVA models were used to assess differences between groups.
Results: Treatment effectively reduced depressive symptoms but did not significantly alter neurometabolite levels in the PCC. Factors such as medication, small sample size, and short follow-up intervals may have contributed to these results.
Impact: This research highlights that, despite effective treatment response in improving depressive symptoms in MDD patients, neurometabolite levels in the PCC were not significantly altered, emphasizing the necessity for further, more extensive research to comprehensively understand MDD and its treatment.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords